STOCK TITAN
  1. Home
  2. News
  3. RCUS

Arcus Biosciences, Inc. - RCUS STOCK NEWS

Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.

Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.

Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.

Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.

Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.

Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.

With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.

News

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

Rhea-AI Summary
Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation TKI, in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors. Patient enrollment for STELLAR-009 is expected to begin before the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
clinical trial
-
News

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

Rhea-AI Summary
Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). The trial is expected to begin enrolling patients before the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
clinical trial
-
News

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary
Arcus Biosciences, Inc. (RCUS) granted new employees options to purchase 12,600 shares of common stock and 6,300 restricted stock units under its 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
News

Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Arcus Biosciences (RCUS) to Participate in Fireside Chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
-
News

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of equity awards to new employees, including options to purchase 31,200 shares of common stock and restricted stock units for 15,600 shares. The awards were granted under the 2020 Inducement Plan approved by the Board of Directors in January 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.15%
Tags
none
-
News

Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update

Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) reports financial results for Q3 2023 and provides pipeline update. Domvanalimab shows promising results in Phase 2 EDGE-Gastric study for upper GI cancers. AB521 exhibits consistent results in cancer patients. Arcus expects to fund operations into 2026 with $950 million in cash and equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
earnings
News

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce promising results from the Phase 2 EDGE-Gastric study, showing encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate in patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. Six-month PFS rates were 93% and 68% for PD-L1-high and PD-L1-low tumors, respectively. Detailed results will be presented at the ASCO Monthly Plenary Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
none
-
News

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce positive results from the Phase 2 EDGE-Gastric study, showing promising overall response rate (ORR) and six-month progression-free survival (PFS) rate. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. The six-month PFS rate was 93% for PD-L1-high tumors and 68% for PD-L1-low tumors. The regimen was well tolerated with a similar safety profile to anti-PD-1 plus chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
none
-
News

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary
Arcus Biosciences grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
News

Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7

Rhea-AI Summary
Arcus Biosciences to present data from Phase 2 study of domvanalimab at ASCO Monthly Plenary Series
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences earnings

FAQ

What is the current stock price of Arcus Biosciences (RCUS)?

The current stock price of Arcus Biosciences (RCUS) is $15.5 as of December 20, 2024.

What is the market cap of Arcus Biosciences (RCUS)?

The market cap of Arcus Biosciences (RCUS) is approximately 1.4B.

What does Arcus Biosciences, Inc. do?

Arcus Biosciences develops innovative immunotherapies for cancer treatment, focusing on the ATP-adenosine pathway.

Where is Arcus Biosciences located?

The company is based in the San Francisco Bay Area, a major center for biotechnology research.

When was Arcus Biosciences founded?

The company was founded in 2015 by a group of seasoned researchers.

What is the core focus of Arcus Biosciences' research?

Arcus focuses on developing small-molecule immuno-oncology product candidates that work on the ATP-adenosine pathway.

What are some of Arcus Biosciences' main products?

Their product pipeline includes Domvanalimab, Etrumadenant, AB598, and Casdatifan.

What types of cancer does Arcus Biosciences target?

The company conducts clinical trials for various cancers, including lung, colorectal, and pancreatic cancers.

Does Arcus Biosciences outsource its research and development?

No, Arcus prides itself on maintaining an internal team of skilled professionals for its R&D efforts.

With whom does Arcus Biosciences have significant partnerships?

Arcus has ongoing collaborations, notably with Gilead Sciences, to advance its research and bring therapies to market.

What makes Arcus Biosciences unique?

The company combines cutting-edge technology with innovative approaches to drug discovery, focusing on both small molecules and biologics.

What is the mission of Arcus Biosciences?

The mission is to create new cancer therapeutics through emerging insights in immunology, providing new hope for patients.

Stock RCUS logo
Arcus Biosciences, Inc.

Nasdaq:RCUS

RCUS Rankings

#2247 Ranked by Market Cap
N/A Ranked by Dividends

RCUS Stock Data

1.41B
54.37M
40.6%
60.08%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAYWARD